Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria | Synapse
March 3, 2026
Evaluation of clinically approved neuroprotective drugs as adjunct therapies in experimental cerebral malaria
PJ
Prince Joshi
SS
Salique Hassan Shaham
RS
Rahul Shivahare
Central Drug Research Institute
Ver todo
Puntos clave
Neuroprotective drugs improved outcomes in experimental cerebral malaria, indicating therapy potential.
Notable improvements were observed in survival rates and neurological function in treated models.
Analysis of neuroprotective drug efficacy, with a focus on adjunct therapy use in cerebral malaria cases.
Highlights the need for further investigation into adjunct therapies for better clinical outcomes.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Joshi et al. (Tue,) studied this question.
synapsesocial.com/papers/69a7603ac6e9836116a2cc16
https://doi.org/https://doi.org/10.1007/s00203-026-04723-x
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir